Day: September 2, 2025

GUELPH, Ontario, Sept. 02, 2025 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) has determined that the recently expanded U.S. tariffs on steel and aluminum derivative products apply to certain materials and components included in many of the Company’s products. The Company expects these tariffs to have a relatively uniform impact across its industry and will work collaboratively with its customers and suppliers to manage and offset the effect of these additional costs. Although there may be short-term implications arising from these changes, at this time, the Company does not anticipate that the tariffs will have a material impact on its business. “While this change in trade policy brings complexity and cost to the industry, we have confidence in our adaptable team and in our strong relationships...

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related DiseaseNEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. “We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases,” said Pablo Legorreta, founder and CEO of Royalty Pharma. “There is clear unmet need in IgG4-RD where obexelimab, with its exciting novel B cell modulating mechanism of action, has...

SCOTTSDALE, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced the launch of the initial public offering of 14,705,882 shares of its Class A common stock. The initial public offering price is currently expected to be between $16.00 and $18.00 per share. Black Rock Coffee Bar expects to grant the underwriters a 30-day option to purchase up to an additional 2,205,882 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. Black Rock Coffee Bar has applied to list its Class A common stock on the Nasdaq Global Market under the ticker symbol “BRCB.” J.P. Morgan, Jefferies, Morgan Stanley and Baird are acting as lead book-running managers for the proposed offering. Stifel and William Blair are acting as additional...

Appointment Strengthens Firm’s European Franchise Across Key Markets NEW YORK and LONDON, Sept. 02, 2025 (GLOBE NEWSWIRE) — Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, announced today that David Wyles has joined the Firm as a Partner. Based in London, Mr. Wyles will assume a leadership role in the Firm’s UK and European Businesses, providing strategic and financial advisory services to clients across sectors. Mr. Wyles joins Perella Weinberg after 27 years at Greenhill & Co., most recently serving as President and Head of Europe, the Middle East and Africa, where he was responsible for originating and executing some of the most significant M&A and restructuring transactions in Europe in recent years. “We are delighted to welcome David to our partnership and to our European...

– Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease – – Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease – WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (Nasdaq: ZBIO), and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. “We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development and into global commercialization. This transaction underscores our conviction in the potential of obexelimab as a franchise...

ANN ARBOR, Mich., Sept. 02, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar, the Company’s lead sericulture expert, has arrived in Southeast Asia to support the production team at its recently established second rearing facility. Dr. Kumar will work directly with the Company’s operations team on the first production cycle at the new center, ensuring the highest levels of quality and efficiency as Kraig Labs continues to expand its BAM-1 spider silk output. His expertise in silkworm rearing and hybrid development has been instrumental to the Company’s success, and his on-site leadership marks a significant step for Kraig Labs in its transition to continuous...

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled “The FDA Gauntlet: Strategies for a Successful Run at Approval” during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany. “Year after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,” said Dr. Musunuri. “I look forward to broadening our reach into the European investment...

IRVINE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Mobix Labs, Inc. (NASDAQ: MOBX), a fabless semiconductor company delivering advanced connectivity solutions for wired and wireless 5G, defense, aerospace, and medical applications today announced it has secured a production contract to deliver custom EMI filter modules enhancing secure communications on U.S. Navy vessels. Navy Greenlights Mobix Technology for Fleetwide Rollout Over the past 18 months, Mobix Labs partnered with a prime U.S. Navy contractor to design, test, and certify custom EMI modules that resolve a discovered susceptibility in shipboard communications. Following rigorous evaluation, Mobix Labs’ solution has been cleared for full-rate production and is being integrated across a wide range of U.S. Navy vessels, underscoring both the versatility of the design and...